Introduction
Aortic stenosis (AS) is nowadays the most frequent valvular heart disease [1] . Although the management of AS has improved over the years with the development of more advanced imaging techniques and novel therapeutic procedures such as transcatheter aortic valve implantation (TAVI), the pathophysiology of AS is not fully understood.
Inflammation and fibrosis are involved in the progression of AS, occurring in both the leaflets and the myocardium due to prolonged exposure to pressure overload [2] . As myocardial fibrosis develops, the left ventricular (LV) diastolic and systolic function become impaired, leading to poorer clinical outcomes including lower long-term survival after aortic valve replacement [3, 4] .
Current guidelines recommend aortic valve replacement in severe AS patients who are symptomatic, have impaired left ventricular ejection fraction (LVEF) <50% or an abnormal exercise test [5] . However, LVEF is not always reliable, as the reported inter-and intra-observer variability can be as high as 10% [6, 7] , and may only become impaired in the late stages of the disease. By contrast, LV global longitudinal strain (GLS) determined by speckle tracking is highly reproducible, and occurs before LVEF impairment in patients with severe AS [8] .
Considering the contribution of inflammation and fibrosis in the progression of AS, the study of biomarkers might also improve patient management. Among novel biomarkers of myocardial fibrosis and inflammation, Galectin-3 has recently gained interest. Galectin-3 is a β-galactoside binding lectin which is upregulated in patients with heart failure [9] ; it has been identified in valvular tissue explanted from patients with AS who underwent aortic valve replacement surgery [10] . Recent studies have shown that elevated Galectin-3 levels predicted poor outcomes after TAVI [11] , suggesting that it may be of use in the management of these patients.
The evolution of severe AS is often complicated by major adverse cardiovascular events (MACEs), including sudden cardiac death, non-fatal myocardial infarction, sustained ventricular arrhythmias, atrial arrhythmias, and hospitalization for heart failure. Several parameters were shown to have predictive values for such events. A reduced GLS predicted cardiovascular mortality and hospitalization for worsening heart failure with higher accuracy than a combined predefined model including the EuroScore, known ischemic heart disease, and LVEF [12] . Among biomarkers of heart failure, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was proved to predict cardiovascular death in severe AS patients [13] , and contribute to risk stratification. However, NT-proB-NP levels do not reflect on-going chronic inflammation.
Considering the involvement of Galectin-3 in the pathophysiology of AS and inflammation, in the current study we aimed to test the predictive ability for MACEs of both GLS and Galectin-3, in addition to NT-proBNP, in patients with severe AS.
Material and Methods

Study patients and design
We conducted a prospective study on 42 consecutive patients with severe AS who were examined in the 2 nd Department of Internal Medicine of the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania between March 2016 and March 2017. Severe AS was defined as 1) peak aortic jet velocity ≥4 m/s, and/or 2) mean transvalvular gradient through the aortic valve ≥40 mmHg, and/or 3) aortic valve area (AVA)≤1.0 cm 2 (or AVA indexed to body surface area ≤0.6 cm 2 /m 2 ) [5, 14] . Patients with other moderate or severe valvular disease, rheumatic or post-irradiation AS, history of coronary artery disease, prior valve replacement surgery, current inflammatory or infectious diseases, known active neoplasia, end-stage renal disease on dialysis, cirrhosis, pulmonary fibrosis, poor echocardiographic window or those who refused to participate in the research were excluded.
The 42 patients in the test group were compared against 42 controls, matched for age and sex. Patients in the control group had no chronic condition except arterial hypertension, symptoms, normal clinical examination, and normal tests results.
The current research was approved by the local Ethics Committee. All patients and controls signed an informed consent before being enrolled. The study was performed in compliance with the Declaration of Helsinki.
Clinical assessment
We recorded the medical history and cardiovascular risk factors of all enrolled subjects (history of smoking, hypertension, hypercholesterolemia, diabetes, obesity). Coronary artery disease was defined as history of myocardial infarction, angina pectoris, or previous revascularization (by either angioplasty or coronary artery by-pass). Dyspnea was graded according to the New York Heart Association (NYHA) functional classification. Patients with AS were considered asymptomatic if they did not exhibit dyspnea, angina, and/or syncope. A 12-lead electrocardiogram was recorded at enrollment and 24-hour Holter monitoring was performed. Exercise capacity was tested by trained technicians using the 6MWT according to American Thoracic Society guidelines [15] ; and the 6-minute walk test distance (6MWD) was recorded.
The risk of mortality after cardiac surgery was assessed by the EuroScore II [16] , using the on-line software available onwww.euroscore.org.
Biochemical analysis
Two peripheral venous blood samples were collected after at least 12 hours of fasting. One blood sample was used for standard biochemistry tests, performed on a Beckman Coulter AU480 Chemistry Analyzer and for determininghs CRP levels by the Sandwich-ELISA method (KAPDB4360 kit, DIA source ImmunoAssays SA, Belgium). The second blood sample was centrifuged and serum was stored at -80°C until the end of the study and used for measuring Galectin-3 and NT-proBNP levels. We used Human GAL3 (Galectin-3) ELISA Kits, Elabscience Biotechnology Co., Ltd kits for Galectin-3 and Sandwich-ELISA kits, Elabscience Biotechnology Co., Ltd for NT-proBNP. Measurements were performed according to the specifications of the manufacturers by a single investigator who was blinded to all other data.
Glomerular filtration rate (eGFR), was estimated by the Chronic Kidney Disease Epidemiology Collaboration equation [17] . Renal function was considered impaired at eGFR <60 mL/min/1.73m 2 .
Echocardiography Transthoracic echocardiography (TTE) was performed using a General Electric Vivid E9 (GE Health Medical, Horten, Norway) echocardiograph with aM5S 1.5/4.6 MHz active matrix phased array transducer. Patients and volunteers in the control group were examined by two investigators working in consensus, with more than 10 years of experience in echocardiography. Investigators were blinded to all clinical and laboratory data.
The severity of AS was graded by peak aortic flow velocity, mean transaortic gradients, and AVA indexed to body surface area (BSA) [18] . LV remodelling was quantified by wall thickness, and LV end-diastolic and endsystolic diameters and volumes, indexed to BSA; left ventricular mass (LVM) calculated by the Devereux formula, and relative wall thickness (RWT) was calculated as 2xLV posterior wall thickness internal LV diameter in diastole. In patients with increased LV mass, concentric hypertrophy was defined as RWT>0.42 and eccentric hypertrophy as RWT≤0.42 [19] .
LVEF was determined by the bi-plane Simpson's modified rule [19] . LV diastolic function and filling pressures were assessed according to the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging [20] .
GLS was determined by 2D speckle tracking from the apical 2-, 3-and 4-chamber views based on the American Society of Echocardiography's 17-segment LV model. In each of the apical views, three sampling points were manually placed on the endocardial border of the septal and lateral mitral annulus, and at the apex. The region of interest was automatically generated and manually edited, aiming at optimum endocardial and epicardial border tracing [21] . Representative cardiac cycles were chosen to determine longitudinal strain, aiming to achieve the best tracking of the myocardium and the most visually satisfying strain curves. Premature beats were excluded. Aortic valve closure was visually identified from the apical long axis view. GLS was calculated as the average of regional strains. The available automated function imaging software package was used for analysis. The software only allowed the calculation of GLS if tracking was adequate in at least five of six segments in each apical view. If more than three segments were not adequately tracked, GLS analysis was not performed.
Right chamber size and function and the probability of pulmonary hypertension were assessed following European Society of Cardiology Guidelines [19, 22] .
Clinical outcomes
Patients were followed-up over a mean interval of 347 days (range 60-450 days) by hospital visits, telephone house-calls, or both. We monitored the occurrence of MACEs -sudden cardiac death, myocardial infarction, sustained ventricular arrhythmias, atrial arrhythmias, and hospitalization for heart failure. Hospitalizations due to non-cardiac causes were not considered. The last evaluation of patient survival status was performed in May 2017 (the follow-up closing date).
Statistical analysis
The normal distribution of data was tested using the Kolmogorov-Smirnoff test for continuous variable distribution. Data with parametric distribution were reported as mean and standard deviation (SD), while data with non-parametric distribution were reported as median and interquartile range (IQR). Relative frequencies for categorical variables were reported as percentages. Comparisons between the test and the control groups were made by the Student's t test for data with Gaussian distribution and the Mann-Whitney test for data with non-Gaussian distribution. Univariable and stepwise multivariable logistic regression analysis was used to identify determinants of Galectin-3, NT-proBNP and GLS. Multivariate Cox proportional hazards regression analysis was performed to detect independent predictors of MACEs. Event-free survival (time to first event) was generated by the Kaplan-Meier method and statistical significance was determined by the log-rank test. Receiver operating characteristic (ROC) curve analysis was performed to study the predictive ability of GLS and biomarkers for MACEs p value <0.05 was considered statistically significant. The statistical analysis was performed using MedCalc Software, version 16.1.2 (Mariakerke, Belgium).
Results
Among the 42 AS patients, 36 underwent surgery for aortic valve replacement. Three other patients refused or postponed surgery, while three were minimally symptomatic and were not scheduled for aortic valve replacement until the end of the study.
The demographic data, clinical characteristics, laboratory data, and echocardiographic findings are detailed in Table I . Patients in the AS group had significantly higher body mass index, and were more often dyslipidemic, active smokers or hypertensive, although no statistically significant differences were recorded between the two groups in terms of systolic and diastolic blood pressures. Differences occurred between the two groups in Galectin-3, NT-proBNP and hsCRP levels, which were significantly higher in AS patients compared with the control group.
In AS patients, the etiology of the valvular disease was calcification of a trileaflet valve (n=34), bicuspid aortic valve (n=4), rheumatic disease (n=2), or undetermined (n=2). The AVA index ranged between 0.40 and 0.60 cm 2 /m 2 . The peak and mean aortic pressure gradients were 74.0 (11.3) mmHg and 45.1 (13.0) mmHg, respectively. .001 Data are presented as mean (standard deviation) or median (IQR) or n (%).n, number patients; IQR, interquartile range; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-Brain Natriuretic Peptide; hsCRP, high sensitive C reactive protein; eGFR, estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA,acetylsalicylic acid; IVSd, diastolic interventricular septum thickness; LVPWd, diastolic left ventricular posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVEF, left ventricular ejection fraction; RWT, relative wall thickness; LAV, left atrial volume; E, peak mitral flow velocity; E', peak myocardial velocity at the mitral valve annulus; DT, early diastolic filling deceleration time; GLS, global longitudinal strain; sPAP, systolic pulmonary artery pressure; 6MWD, six minute walk distance; TAPSE, tricuspid annular plane systolic excursion; AVA, aortic valve area. n, number patients; NT-proBNP, N-terminal pro-Brain Natriuretic Peptide; hsCRP, high sensitive C reactive protein; eGFR, estimated glomerular filtration rate; IVSd, diastolic interventricular septum thickness; LVPWd, diastolic left ventricular posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVEF, left ventricular ejection fraction; RWT, relative wall thickness; LAV, left atrial volume; E, peak mitral flow velocity; E', peak myocardial velocity at the mitral valve annulus; DT, early diastolic filling deceleration time; GLS, global longitudinal strain; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; AVA, aortic valve area; 6MWD, six minute walk distance; NS, not significant.
In the AS group, LV wall thickness was significantly increased compared to the control group, as were the RWT and LV mass, while LVEF was lower. The E/E' ratio was higher in test group patients, also exhibiting a larger LAV index, increased sPAP and lower TAPSE.
Importantly, GLS was significantly lower in AS patients compared with the control group.
We further tested correlations between Galectin-3 and NT-proBNP levels, and significant parameters of AS severity (mean gradients and AVA), as well as indices of LV remodelling and dysfunction -RWT, LVM index, LVEF and GLS. There were no correlations between the echocardiographic parameters of AS severity and any of the tested biomarkers. Both Galectin-3 and NT-proBNP levels were, however, positively correlated to the LVM index, RWT and negatively to GLS. NT-proBNP correlated significantly and inversely to LVEF, while Galectin-3 levels did not. Correlations between NT-proBNP levels and LVEF were only weak, despite reaching statistical significance. Both biomarkers correlated negatively to 6MWDs and to eGFR (Table II) .
Among the 42 patients with AS, 15 had MACEs: death (n=1) non-fatal myocardial infarction (n=1), sustained ventricular arrhythmias (n=1), atrial arrhythmias (n=5), and hospitalization for heart failure (n=10). Univariable analysis by logistic regression yielded statistically significant direct correlations between Galectin-3, NT-proBNP and CRP levels and the occurrence of MACEs. Increased LV end-systolic volume, RWT, E/E' ratio and impaired GLS were also associated with MACEs. In multivariable analysis, only the correlations to NT-proBNP levels and GLS remained statistically significant (Table III) .
Kaplan-Meier analysis assessing correlations between GLS <-14.9% and NT-proBNP >3900 pg/mL and overall MACEs occurrence, showed that the probability of freedom from MACEs was significant in patients who exhibited lower GLS [HR 2.73 The predictive power of GLS for identifying patients with MACEs was slightly lower than that of NT-proBNP, but higher than that of Galectin-3 or other echocardiographic parameters such as LVEF, LVM index, or RWT (Table IV) .
Discussions
In the current study, we aimed to assess the diagnostic and prognostic ability of GLS and Galectin-3 in patients with severe AS. Among echocardiography parameters, GLS performed best, having a higher sensitivity than the LVEF, LVM index, and RWT for identifying patients with cardiovascular events: the specificity was however, lower than that of LVEF.
The high sensitivity of GLS was confirmed in previous studies; GLS was shown to detect early systolic dysfunction [8, 23] , to associate with MACEs [24] , and provide incremental value to clinical parameters, including the EuroScore, for predicting mortality in AS patients with preserved [25] or mildly impaired LVEF [12] . Moreover, Gelsomino et al showed that, in patients with AS and preserved LVEF, GLS could accurately predict LVM regression after aortic valve replacement [26] .
Although Galectin-3 levels were significantly higher in patients with AS than in controls, and correlated moderately to echocardiographic parameters of LV remodelling such as LVM index and RWT, and strongly to GLS, it failed to accurately predict MACEs. After adjustment for confounding factors in multivariate analysis, it no longer correlated with MACEs, while GLS and NT-proBNP did.
Our results are consistent with previously published data. Although Galectin-3 is known to be involved in inflammation and the development of fibrosis [4] , its clinical use is hindered by the fact that it is not specific for identifying myocardial fibrosis. In our study, as well as in previously published research, confounding factors [27, 28] , which is an important issue considering the fact that many patients with cardiovascular disease, particularly heart failure, evidence associate kidney dysfunction [29] . In the research by Bobrowska et al, Galectin-3 levels were weakly associated with medium-term mortality in patients undergoing surgical or interventional treatment of severe AS, but the correlation was lost after adjustment for eGFR. Galectin-3 levels >17.8 ng/mL only predicted mortality in the subgroup treated by balloon aortic valvuloplasty, even after adjustment for eGFR and valvulo-arterial impedance [28] . Interestingly, Baldenhofer et al [11] reported that Galectin-3 predicted outcomes after TAVI independently of age, sex, glomerular filtration rate, and NT-proBNP [11] . In a recent study Galectin-3 was not associated with either AS severity, or functional status, and did not provide prognostic information on the occurrence of AS-related events [27] . Unlike Galectin-3, NT-proBNP performed well, yielding the most reasonable sensitivity and specificity for the occurrence of MACEs. This is consistent with data from previous studies. In a series of 1953 consecutive patients with at least moderate AS, BNP clinical activation, defined as measured BNP/age was associated with higher longterm mortality [30] . Moreover, BNP levels, particularly in combination with echocardiographic markers of LV dysfunction, were shown to anticipate the development of symptoms in asymptomatic patients with severe AS [31] and to predict clinical outcomes [32] in such patients.
It is possible that, in the future, BNP or NT-proBNP, as well as echocardiographic markers of LV function impairment such as GLS, might contribute to the selection of asymptomatic AS patients for early surgery. The role of Galectin-3 in the management and prognostic assessment of AS patients remains, however, uncertain.
The current study has some limitations generated by the rather low number of patients and the fact that patient follow-up was limited to as little as 60 days for the last enrolled subjects. Further, investigations by echocardiography and Galectin-3 levels were only performed at enrollment and were not repeated afterwards by the investigators involved in the current study. Further research on a larger number of patients and with an extended period of follow-up is needed to endorse the results of the current study.
Conclusions
In our study, the best predictors of MACEs in patients with severe AS undergoing surgery were NT-proBNP levels and reduced GLS. Although Galectin-3 levels correlated well with echocardiographic parameters of LV remodelling and dysfunction, it did not predict MACEs after adjustment for confounding factors.
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